Single-dose-administration study of GT-02037 subcutaneous injection in healthy Japanese male subjects
Phase of Trial: Phase II
Latest Information Update: 03 Nov 2017
At a glance
- Drugs GT 02037 (Primary)
- Indications Acromegaly
- Focus Adverse reactions
- Acronyms GT-02037 single dose study
- Sponsors Pharmaspur Inc
- 01 Nov 2017 Status changed from active, no longer recruiting to completed.
- 04 Sep 2017 Status changed from recruiting to active, no longer recruiting.
- 28 Jul 2017 New trial record